The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting.
about
Cardiac cachexia: hic et nuncMuscle plasticity and β₂-adrenergic receptors: adaptive responses of β₂-adrenergic receptor expression to muscle hypertrophy and atrophyCreb coactivators direct anabolic responses and enhance performance of skeletal muscleBeta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis.Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle.Cancer cachexia: mechanisms and clinical implications.Insulin/IGF-1 signaling, including class II/III PI3Ks, β-arrestin and SGK-1, is required in C. elegans to maintain pharyngeal muscle performance during starvation.Randomized, double-blind, and placebo-controlled trial of clenbuterol in denervated muscle atrophy.cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regenerationMolecular and cellular mechanisms of skeletal muscle atrophy: an update.Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.Risk of sepsis in patients with amyotrophic lateral sclerosis: a population-based retrospective cohort study in Taiwan.Emerging drugs for treating skeletal muscle injury and promoting muscle repair.Mechanisms modulating skeletal muscle phenotype.The role of catecholamines in mesenchymal stem cell fate.The wasting continuum in heart failure: from sarcopenia to cachexia.Skeletal muscle regeneration in cancer cachexia.Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice.Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs.Clenbuterol Induces Cell Cycle Arrest in C2C12 Myoblasts by Delaying p27 Degradation through β-arrestin 2 Signaling.Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?No evidence of cardiomyopathy in spinal and bulbar muscular atrophy.Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats.Association of the ADRB2 Gly16Arg and Glu27Gln polymorphisms with athlete status.The β2-adrenoceptor agonist formoterol improves structural and functional regenerative capacity of skeletal muscles from aged rat at the early stages of postinjury.
P2860
Q26744140-8AE794AE-EC83-409E-B0BE-B54AFD2AE908Q27016049-E0AA0D4E-1714-4699-BC10-82DB337B6E87Q28507328-C47C3F84-773C-44F1-ACF2-50E0BF6B29C5Q33771137-F71B640D-3CE4-4004-8D3F-A849ABF0B67DQ33817082-0A9A77F4-7321-4DF7-8323-39E2AB2FA4DAQ34631019-FA758237-F536-47B5-B79D-11CA542E0232Q34735251-79FDFEFC-B30A-4BD2-8B0C-3786A550B427Q35687767-A9ED8D3C-C92E-44F2-A9CF-42B33C7629B9Q36114861-9A4EF738-B6D9-4E93-937E-AE709529B43CQ36179105-42BAE0AF-610D-4A93-8915-E3238F5CCB93Q36482927-3ED005BB-7C4F-4B80-B853-4A7FEDBEDEBAQ37528272-A7B4F102-DAB0-4347-9734-4D5CB03D272DQ37598197-CA7DE431-7DF0-422F-BE7A-3D24A9E66AC6Q37842502-E32BCDF5-2210-43F1-837A-6B761DD19B21Q38165143-7C731C0C-515C-4F41-B8EB-57049FE74CD8Q38244904-6DFC6AC7-9A04-4A21-8FCA-085487DA5D05Q38564746-DF5D1D60-8EDC-476E-B50E-B11D121D8305Q38726702-BE687931-5DF9-4A15-AD4B-0FAEB07D9A55Q39093151-C6422460-5F5D-4FB6-B522-FF2DB27A83F3Q43159102-9A4F1747-D5B1-4DD6-AEB1-576699E80A74Q44510653-7E2A0AA0-EA03-4D19-8223-B69DF92F5652Q44991576-784A981A-CE02-4E85-8E6D-998DFDB79E7AQ45176977-6BF98B7C-32C8-4631-92D7-CD7C72D00E7DQ47130400-113251DD-AF92-41EA-B203-4109AF1A4A7AQ51029544-EE3F6D21-65EE-4EAD-8CB5-3FA19B19C7DDQ54547731-A5B5F23F-ABF3-42CC-827C-8D15569B208F
P2860
The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@en
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@nl
type
label
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@en
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@nl
prefLabel
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@en
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@nl
P1476
The potential and the pitfalls ...... nt of skeletal muscle wasting.
@en
P304
P356
10.1016/J.PHARMTHERA.2008.06.003
P577
2008-09-16T00:00:00Z